| Jeffrey Jacob Schenk, DO | |
|
1303 N Main St, Cedar City, UT 84721-9746 | |
| (435) 868-5567 | |
| Not Available |
| Full Name | Jeffrey Jacob Schenk |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 13 Years |
| Location | 1303 N Main St, Cedar City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710285929 | NPI | - | NPPES |
| 07307039 | Medicaid | CO | |
| P01381223 | Other | CO | RAILROAD MEDICARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cedar City Hospital | Cedar city, UT | Hospital |
| Dixie Regional Medical Center | St george, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.
Toxic Shock Syndrome (TSS) is a severe circulatory and organ failure caused by bacterial toxins, usually triggered by bacteria from the Staphylococcus group. Researchers from MedUni Vienna's Department of Clinical Pharmacology, in collaboration with the company Biomedizinische Forschungsgesellschaft mbH in Vienna, have now developed the world's first safe and effective vaccine against this disease and successfully tested it in a Phase I trial.
St. Jude Medical, Inc., a global medical device company, and LightLab Imaging, Inc. today announced a definitive agreement under which St. Jude Medical will acquire LightLab, a subsidiary of Goodman Co., Ltd. for approximately $90 million in cash.
Ingen Technologies, Inc.is an established medical device manufacturer with an emerging new medical product line targeting the rapidly growing $8 billion global respiratory market. The company recently announced that the pre-recorded interview from Wednesday with CEO, Scott Sand, will be aired again on The Money Channel's American Scene Radio with host Steve Crowley today at 11:24 AM Eastern Daylight Time.
› Verified 5 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.
Toxic Shock Syndrome (TSS) is a severe circulatory and organ failure caused by bacterial toxins, usually triggered by bacteria from the Staphylococcus group. Researchers from MedUni Vienna's Department of Clinical Pharmacology, in collaboration with the company Biomedizinische Forschungsgesellschaft mbH in Vienna, have now developed the world's first safe and effective vaccine against this disease and successfully tested it in a Phase I trial.
St. Jude Medical, Inc., a global medical device company, and LightLab Imaging, Inc. today announced a definitive agreement under which St. Jude Medical will acquire LightLab, a subsidiary of Goodman Co., Ltd. for approximately $90 million in cash.
Ingen Technologies, Inc.is an established medical device manufacturer with an emerging new medical product line targeting the rapidly growing $8 billion global respiratory market. The company recently announced that the pre-recorded interview from Wednesday with CEO, Scott Sand, will be aired again on The Money Channel's American Scene Radio with host Steve Crowley today at 11:24 AM Eastern Daylight Time.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey Jacob Schenk, DO Po Box 27128, Salt Lake City, UT 84127-0128 Ph: () - | Jeffrey Jacob Schenk, DO 1303 N Main St, Cedar City, UT 84721-9746 Ph: (435) 868-5567 |
News Archive
GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.
Toxic Shock Syndrome (TSS) is a severe circulatory and organ failure caused by bacterial toxins, usually triggered by bacteria from the Staphylococcus group. Researchers from MedUni Vienna's Department of Clinical Pharmacology, in collaboration with the company Biomedizinische Forschungsgesellschaft mbH in Vienna, have now developed the world's first safe and effective vaccine against this disease and successfully tested it in a Phase I trial.
St. Jude Medical, Inc., a global medical device company, and LightLab Imaging, Inc. today announced a definitive agreement under which St. Jude Medical will acquire LightLab, a subsidiary of Goodman Co., Ltd. for approximately $90 million in cash.
Ingen Technologies, Inc.is an established medical device manufacturer with an emerging new medical product line targeting the rapidly growing $8 billion global respiratory market. The company recently announced that the pre-recorded interview from Wednesday with CEO, Scott Sand, will be aired again on The Money Channel's American Scene Radio with host Steve Crowley today at 11:24 AM Eastern Daylight Time.
› Verified 5 days ago